Eisai reports Phase Ib/II data for Halaven plus Keytruda in TNBC
Eisai Co. Ltd. (Tokyo:4523) reported data from 106 evaluable patients with metastatic triple-negative breast cancer (TNBC) in the Phase Ib/II ENHANCE 1 (KEYNOTE-150) trial showing that Halaven eribulin mesylate (E7389) plus anti-PD-1 mAb Keytruda pembrolizumab led to an objective response rate (ORR), the Phase II primary endpoint, of 26.4%, including 3 complete responses and 25 partial responses. Eisai said ORRs were similar irrespective of PD-L1 status or prior chemotherapy. One of the three complete responders was PD-L1-negative. Data were presented at the San Antonio Breast Cancer Symposium.
On secondary endpoints, Halaven plus Keytruda led to a median progression-free survival (PFS) of 4.2 months, overall survival (OS) of 17.7 months and duration of response of 8.3 months...